ORG Partners LLC Invests $266,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

ORG Partners LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 1,700 shares of the biotechnology company’s stock, valued at approximately $266,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the period. Vanguard Capital Wealth Advisors lifted its position in Sarepta Therapeutics by 3.8% in the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after purchasing an additional 90 shares during the period. Riggs Asset Managment Co. Inc. lifted its position in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the period. WCM Investment Management LLC lifted its position in Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after purchasing an additional 142 shares during the period. Finally, New York Life Investment Management LLC lifted its position in Sarepta Therapeutics by 1.7% in the fourth quarter. New York Life Investment Management LLC now owns 9,942 shares of the biotechnology company’s stock worth $959,000 after purchasing an additional 166 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRPT has been the subject of a number of research analyst reports. BMO Capital Markets upped their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. Robert W. Baird upped their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, June 21st. Mizuho upped their target price on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Citigroup cut their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $165.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 21st. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $186.22.

Insider Activity

In other news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Down 0.3 %

NASDAQ:SRPT traded down $0.38 during trading hours on Wednesday, hitting $133.08. 1,070,906 shares of the stock traded hands, compared to its average volume of 1,393,993. The firm has a 50 day moving average price of $141.27 and a 200 day moving average price of $131.75. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The firm has a market cap of $12.58 billion, a price-to-earnings ratio of 1,213.27 and a beta of 0.89.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period in the previous year, the business earned ($0.27) EPS. The company’s revenue was up 38.9% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.